한국투자證 “삼성바이오로직스, 유증·파업에도 중장기 성장 기대…목표가 195만원 상향"
Read the full article on 조선일보 →KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.
Read the full article on 조선일보 →KioskNews shows the publisher’s own headline, image, and summary — the full article always lives on their site, not ours.
Pick a conversation — tap 💬 on any story